Back to News
Dec 18, 2025 8:40 AM

Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs)

Proceeds will support the advancement of Atavistik Bio's oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms (MPNs) through clinical proof of concept

Atavistik Bio anticipates initiating its clinical trial in HHT in the first half of 2026

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Atavistik Bio, a biotechnology company discovering the next generation of precision allosteric therapeutics, today announced that it has raised a $120 million Series B financing to support the advancement of selective allosteric small molecule therapeutics for the treatment of HHT and MPNs. The financing was led by Nextech Invest and The Column Group, with participation from existing investor Lux Capital and new investor Regeneron Ventures. Atavistik Bio will use the proceeds from the Series B financing to advance its oral allosteric AKT1-selective inhibitor for HHT and its JAK2 V617F mutant-selective inhibitor program for MPNs through clinical proof of concept.

"We're thrilled to announce our Series B financing, and grateful for the support of both our existing and new investors. With this capital, we are well-positioned to advance both our HHT and MPN programs through key clinical proof-of-concept milestones, with the HHT program expected to enter the clinic in the first half of 2026," said Bryan Stuart, Chief Executive Officer at Atavistik Bio. ...